EUVIMEDEUVIMED entdecken
Crossref

Perspective: The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of Car-T Therapy Products

Miroslava Jandová, Glyn Nigel Stacey, Miriam Lánská, Jií Gregor, Petra Rozsívalová, Lenka Beková, Zuzana Woidigová Ducháová, David Belada, Jakub Radocha, Pavel Měřička, Barry Fuller

Cryoletters · 01.05.2023 · 44 (3) · 123-133

DOI: 10.54680/fr23310110112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cryoletters, erschienen am 01.05.2023. Verfasst von Miroslava Jandová und 10 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several clinical trials have proved the efficacy and safety of T-cells chimeric antigen receptor (CAR-T cells) in treatment of malignant lymphoma and the first products were registered in the European Union in 2018. The shelf-life of CAR-T cell products in the liquid state is short, so cryopreservation offers a significant benefit for logistics in manufacturing and patient management. Direct shipment of the cryopreserved CAR-T cell therapy products to the clinical department is feasible, nevertheless, intermediate storage in the hospital cryostorage facility gives significant advantage in planning of their administration to patients. Moreover, some manufacturers prefer transport of the starting material cryopreserved at the collection site. The cryopreservation protocol used for starting material by the authors is based on combining dimethyl sulphoxide (DMSO) with hydroxyethyl starch (HES) and slow controlled cooling in cryobags housed in metal cassettes. This achieves the mononuclear cell post-thaw viability of 98.8 ± 0.5 % and recovery of 72.8, ± 10.2 %. Transport of the starting material to the manufactures and return transport of the CAR-T therapy product is performed by authorized courier companies. Intermediate cryostorage of the final CAR-T cell therapy product is performed in a separate dry-storage liquid nitrogen container. On the day of infusion, the cryopreserved products are transported to the clinical department in a dry shipper. On the wards the product is removed from the cassette, inserted into a sterile plastic bag, thawed in a 37 °C water bath followed by immediate intravenous administration. The authors discuss the adherence of the used technology to good manufacturing practice (GMP) principles and genetic safety assurance rules.

Zitieren

APA

Jandová, M., Stacey, G. N., Lánská, M., Gregor, J., Rozsívalová, P., Beková, L., Ducháová, Z. W., Belada, D., Radocha, J., Měřička, P., & Fuller, B. (2023). Perspective: The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of Car-T Therapy Products. Cryoletters, 44(3), 123-133. https://doi.org/10.54680/fr23310110112

Vancouver

Jandová M, Stacey GN, Lánská M, Gregor J, Rozsívalová P, Beková L, et al. Perspective: The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of Car-T Therapy Products. Cryoletters. 2023;44(3):123-133. doi:10.54680/fr23310110112

BibTeX
@article{Jandov2023,
  author = {Jandová, Miroslava and Stacey, Glyn Nigel and Lánská, Miriam and Gregor, Jií and Rozsívalová, Petra and Beková, Lenka and Ducháová, Zuzana Woidigová and Belada, David and Radocha, Jakub and Měřička, Pavel and Fuller, Barry},
  title = {Perspective: The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of Car-T Therapy Products},
  journal = {Cryoletters},
  year = {2023},
  volume = {44},
  number = {3},
  pages = {123--133},
  doi = {10.54680/fr23310110112}
}
Kostenlos starten →